ASH 2022: Recent Advances in Chronic Myeloid Leukemia

Experts in hematologic oncology review and analyze updated data in chronic myeloid leukemia from ASH 2022.

Data from the following clinical trials are discussed:

  • 620: Three-Year Update from the OPTIC Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib
  • 333: Outcome of Third-Line Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in Chronic Phase: A Propensity Score Analysis
  • 3009: Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial
  • 4339: Outcomes in Patients with Chronic Myeloid Leukemia in the Chronic Phase Randomized to Dasatinib or Imatinib after Suboptimal Responses to 3 Months of Imatinib Therapy: Final 5-Year Results from DASCERN

Supported in part by Amgen Oncology, Servier, and Takeda Oncology. Content developed independently by OncLive®.

Related Videos
Expert on urothelial carcinoma
Expert on urothelial carcinoma
Naveen Pemmaraju, MD, an expert on myeloproliferative neoplasms
Pankit Vachhani, MD, an expert on myeloproliferative neoplasms
Shannon N. Westin, MD, MPH, FACOG
Experts on CRC
Expert on CRC
Jorge E. Cortes, MD
Bradley W. Christensen, MD
Expert on urothelial carcinoma
Related Content